Navigation Links
Double Helix Strengthens its Strategic Pricing and Reimbursement Practice with Hire of Caryn Zieses
Date:7/20/2009

NEW YORK, July 20 /PRNewswire/ -- Double Helix Consulting US, a division of London-based Double Helix Development group, today announced the appointment of Caryn Zieses to the position of Senior Consultant. Zieses joins a multidisciplinary team of highly experienced strategic pricing, reimbursement and market access consultants with extensive experience across the healthcare industry, which provides product commercialization services to firms in the pharmaceutical, biotechnology and medical device industries. DHC US provides services spanning the product lifecycle, including the following:

  • Product value message development and testing
  • Commercial assessment
  • Development program and clinical trial planning
  • Managed markets strategy
  • Pharmacoeconomic evaluation and health technology assessment
  • Payer and provider insight evaluation and influence planning
  • Pricing and reimbursement strategy, negotiation simulation, and training

Drew Baker, President of Double Helix Consulting US, commented, "Caryn complements our international market access, pricing and reimbursement capabilities through her vast experience in planning and implementing product development and launch strategies for the US market. Her intimate knowledge of managed care market structure, formulary management, contracting strategies, and marketing communications strengthens Double Helix's ability to meet our clients' commercial objectives in the increasingly cost-conscious and value-driven US market."

Chief Executive Officer of Double Helix Development Group, Dr. Wayne Phillips, added, "Double Helix Consulting offers a premier set of services to assist our clients in optimizing product commercialization by enhancing market access through a truly global team of professionals with deep experience from both the client and consulting sides. As an example, our growing emerging markets practice provides clients with the intelligence to implement successful strategies in the world's largest and most rapidly developing economies. Caryn's experience in product planning and launch strategy bolsters our expanding capabilities."

Zieses joins the Double Helix Consulting US team from the Pricing & Reimbursement consulting practice of IMS Health. She has worked closely with both large and small pharmaceutical and biotech clients to deliver global strategic recommendations that would inform decisions related to drug pricing, market access, clinical trial design, value messaging, payer attitudes, forecasting, and commercial assessments. Her expertise in US payer trends spans both public and private organizations and the policy changes they continually face. She has extensive experience in a diverse set of therapy areas, in particular those related to neurosciences, pulmonology, immunology and ophthalmology. She also has four years of previous client services experience in the Equity Research division of Lehman Brothers. Caryn holds an MBA from the Kellogg School of Management, an MEM from Northwestern University, and a BSE in Chemical Engineering from the University of Pennsylvania.

http://www.doublehelixdevelopment.com

(Photo: http://www.newscom.com/cgi-bin/prnh/20090720/NY49139 )

(Logo: http://www.newscom.com/cgi-bin/prnh/20090330/NY91277LOGO )


'/>"/>
SOURCE Double Helix Consulting US
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Honeywell to Help B. Braun Healthcare Company Double Manufacturing Capacity of Life-Critical Products
2. Double Helix Appoints Ann Stuchiner Vice President of US Consulting Division
3. Nanoparticles double their chances of getting into sticky situations
4. Carbon nanotube avalanche process nearly doubles current
5. SleepQuest Compliance Again Doubles Industry Average
6. London-Based Double Helix Consulting Launches US Division for Strategic Pricing, Reimbursement and Market Access Solutions
7. Rising H9N2 Influenza Replikin Count Has Doubled That of H5N1
8. YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER
9. Method sorts out double-walled carbon nanotube problem
10. Premier Research Achieves Double-Digit Growth in Functional Sourcing for the Third Straight Year
11. US Neuropathic Pain Market Value Doubles to $5 Billion by 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... TOKYO , June 24, 2016  Regular discussions on ... to take place between the two entities said Poloz. ... in Ottawa , he pointed to the ... and the federal government. ... Poloz said, "Both institutions have common economic goals, why not ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica ... in people with peritoneal or pleural mesothelioma. Their findings are the subject of a ... , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... , June 23, 2016 Houston Methodist ... the Cy-Fair Sports Association to serve as their ... agreement, Houston Methodist Willowbrook will provide sponsorship support, ... connectivity with association coaches, volunteers, athletes and families. ... the Cy-Fair Sports Association and to bring Houston ...
Breaking Biology Technology:
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
(Date:5/9/2016)... May 9, 2016 Elevay is ... to expanding freedom for high net worth professionals seeking ... today,s globally connected world, there is still no substitute ... ever duplicate sealing your deal with a firm handshake. ... by taking advantage of citizenship via investment programs like ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
Breaking Biology News(10 mins):